Formycon Shares Jump 13% After FDA Accepts Keytruda Biosimilar Application
Formycon and Zydus Lifesciences said the FDA accepted their application for review of a biosimilar version of Merck’s Keytruda. Formycon shares were up 13% in Europe.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.